Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) Invested Capital (2018 - 2025)

Neurogene's Invested Capital history spans 6 years, with the latest figure at $264.9 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 14.67% year-over-year to $264.9 million; the TTM value through Dec 2025 reached $264.9 million, down 14.67%, while the annual FY2025 figure was $264.9 million, 14.67% down from the prior year.
  • Invested Capital reached $264.9 million in Q4 2025 per NGNE's latest filing, roughly flat from $265.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $310.5 million in Q4 2024 to a low of -$183.2 million in Q3 2023.
  • Average Invested Capital over 3 years is $128.8 million, with a median of $178.5 million recorded in 2023.
  • Peak YoY movement for Invested Capital: skyrocketed 208.42% in 2024, then decreased 14.67% in 2025.
  • A 3-year view of Invested Capital shows it stood at $186.1 million in 2023, then skyrocketed by 66.79% to $310.5 million in 2024, then dropped by 14.67% to $264.9 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Invested Capital are $264.9 million (Q4 2025), $265.5 million (Q3 2025), and $273.3 million (Q2 2025).